参考文献
[1]王振义,李家增,阮长耿,等.血栓与止血基础理论与临床[M].3版.上海:上海科学技术出版社,2004:300-399.
[2]林果为,欧阳仁荣,陈珊珊,等.现代临床血液病学[M].上海:复旦大学出版社,2013:1460-1482.
[3]黄绍良,陈纯,周敦华.实用小儿血液病学[M].北京:人民卫生出版社,2014:434-455.
[4]张之南,沈悌.血液病诊断及疗效标准[M].3版.北京:科学出版社,2008:191-195.
[5]蒋与刚,高志贤.营养基因组学[M].北京:科学出版社,2012:294-309.
[6]济阳高穗.癌细胞害怕我们这样吃[M].鲁雯霏译.南昌:江西科学技术出版社,2015:24-28.
[7]杨宝峰.基础与临床药理学[M].2版.北京:人民卫生出版社,2014:252-263.
[8]陈吉生.新编临床药物学[M].北京:中国中医药出版社,2013:547-555.
[9]沈丕安.中药药理与临床运用[M].北京:人民卫生出版社,2006:75-998.
[10]中化医学会血液学分会血栓与止血学组,中国血友病协作组.血友病诊断与治疗中国专家共识(2013年版)[J].中华血液学杂志,2013,34(5):461-463.
[11]真木正博.止血の実際[M].东京:金原出版株式会社,1970:1-200.
[12]刘陕西.止血剂的合理应用[M].西安:陕西科学技术出版社,1986:2-98.
[13]刘陕西.出血性疾病:内科学表解[M].西安:陕西科学技术出版社,1987:111-118.
[14]郑士敏.骨科必读[M].北京:人民卫生出版社,2014:294-299.
[15]T Duckworth,C M Blundell.临床笔记:骨科学[M].刘培来,李德强,张元凯译.济南:山东科学技术出版社,2014:74-80.
[16]宁志杰,孙磊,吴复元.现代骨科临床检查诊断学[M].北京:人民军医出版社,2007:2-9.
[17]Yong Ren-chi.Comments on Chinese experts consensus on the diagnosis and treatment of acguired hemophilia A[J].J Cin Hematol(China),2004,27(7):547-549.
[18]Franchina M, Lippi G, Favaloro E J.Acquired inhibitors of coagulation factors:part 11[J].Scnin Throml,Hemosi, 2012,38:447-453.
[19]Coppoi A A, Favaloro E J, Tufanno A, et al.Acquired inhibitors of coagulation factors:part I-acquired hemophilia A[J].Semin Thromb Hemost, 2012,38:433-446.
[20]Knoebi P, Marco P, Baudo F, et al.Demographic and clinical data in acquired hemophilia A: results form the European acquired Haemophilia Registry(EACH2)[J].J Thromb Homeost, 2012, 10:622-631.
[21]Collins P, Baudo F, Knoebl P, et al.Immunosuppression for acquired haemophilia A:results from the European Acquired Haemophilia Reqistry(EACH2)[J].Blood,2012, 120:47-55.(https://www.daowen.com)
[22]Baudo F, Conllins P, Huth-Kuhne A, et al.Management of bleeding in acquired hemophilia A:results from the European Acquired Haemophilia(EACH2)Registry[J].Blood, 2012, 120:39-16.
[23]Tengborn L, Baudo F, Huth-Kuhne A, et al.Pregnancy-associated acquired Haemophilia A.results from the European Acquired Haemophilia(EACH2)registry[J].BJOG, 2012, 119:1529-1537.
[24]Huth-Kuhne A, Baudo F, Collins P, et al.International recommendations on the diagnosis and treatment of patients with acquired hemophilia A[J].Haematologica,2009, 94:566-575.
[25]Yang Y, Xue F, Shi H, et al.Acquired hemophilia A: Retrospective analysis of 49 cases from a single Chinese hemophilia center[J].Clin Appl Thromb Hemost, 2013,May 14.
[26]Gupta S,Siddiqi A E,Soucie J M,et al.The effect of secondary prophylaxis versus episodic treatment on the range of motion of target joints in patients with maemophilia[J].Br J Haematol,2013,161:424-433.
[27]Srivastava A,Brewer A K,Mauser-bunschoten E P,et al.Guidelines for the management of hemophilia[J].haemophilia,2013,19:e1-e47.
[28]杨仁池,王鸿利.血友病[M].上海:上海科学技术出版社,2007:195-213.
[29]丁培芳,张志传,张心声,等.血友病A患者抗-HCV和抗-HIV阳性率调查分析[J].中国输血杂志,2002,15:212-213.
[30]叶仕高.内科学[M].北京:人民卫生出版社,2004:663-666.
[31]Arruda V R, Schuettrumpf J, Herzog R W,et al.Safety and defficacy of factor Ⅸgene transfer to skeletal muscle in murine and canine hemophilia B models by adenoassociated viral vector serotype I[J].Blood, 2004, 103(1): 85-92.
[32]Follenxi A, Battaglia M, Lombardo A, et al.Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor Ⅸ in mice[J].Blood, 2004, 103(10):3700-3709.
[33]Gilles J, Grailly S, Maeyer M, et al.In vivo neutralization of a C2 do main-specific human anti-Factor Ⅷ inhibitor by an anti-idiotypic an tibody[J].Blood, 2004, 103(7): 2617-2623.
[34]Liu Shanxi, Jiang Lin, Liu Yiguo, et al.The effect and safety research on treatment of hemophilia with the Xueyou Mixture[J].Chin J Integr Tradit West Med,2007,13(2):141-142.
[35]Liu Shanxi, Jiang Lin, Liang Xin, et al.Study on classified curing hemophilic arthritis by integration traditional Chinese and Western medicine[J].Chin J Integr Tradit West Med,2007, 13(4): 301~305.
[36]张之南.血液病诊断及疗效标准[M].北京:科学出版社,1998:304-311.
[37]Von Depka M.Immune tolerance therapy in patients with acquired hemophilia[J].Hematology, 2004, 9(4):245-257.
[38]Lei T C, Scott D W.Induction of tolerance to factor Ⅷ inhibitors by genetherapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins[J].Blood, 2005, 105(12):4865-4870.
[39]Fay P J, Jenkins P V.Mutating factor Ⅷ: lessons from structure to function[J].Blood Rev, 2005, 19(1): 15-22.
[40]Rodriguez M H, Plantier J L, Enjolras N, et al.Biosynthesis of FⅧ in megakaryocytic cells: improved production and biochemical characterization[J].Br J Haematol,2004, 127(5): 568-575.
[41]Mohanty D, Ghosh K, Shetty S, et al.Mutations in the MCFD2 gene and a novel mutation in the LMAN 1gene in Indian families with combined deficiency of factor V andⅧ[J].Am J Hematol, 2005, 79(4):262-266.
[42]丕安.中药药理与临床运用[M].北京:人民卫生出版社,2006:75-831.